Plasma S100A12 Levels and Peripheral Arterial Disease in End-Stage Renal Disease by Shiotsu, Yayoi et al.
242
    © 2011 S. Karger AG, Basel
 Original  Paper 
  Nephron Extra 2011;1:242–250 
  Plasma S100A12 Levels and 
Peripheral Arterial Disease in
End-Stage Renal Disease 
 Yayoi  Shiotsu    a      Yasukiyo Mori     a      Tsuguru Hatta     b      Noboru Maki     c     
Kumiko Iida     c      Eiko Matsuoka     a      Hiroshi Kado     a      Ryo Ishida     a      
Noriko Kishimoto     a      Keiichi Tamagaki     a      Masato Nishimura     d      
Noriyuki Iwamoto     d      Toshihiko Ono     d      Hiroaki Matsubara     a      
Atsushi Kosaki     e    
  a     Department of Cardiology and Nephrology, Kyoto Prefectural University of Medicine, 
 Kyoto ,   b     Renal Division, Omihachiman Community Medical Center,   Omihachiman  , 
  c     Advanced Life Science Institute, Saitama,   d     Cardiovascular Division, Tojinkai Hospital, 
 Kyoto ,  and   e     Department of Medicine II, Kansai Medical University,   Hirakata  , Japan
 
 Key  Words 
 S100A12      Peripheral arterial disease      Chronic kidney disease      Receptor for advanced 
glycation end products 
 Abstract 
  Background:   S100A12 is an endogenous ligand of the receptor for advanced glycation end 
products (RAGE). Plasma S100A12 levels are high in end-stage renal disease (ESRD) patients un-
dergoing maintenance hemodialysis (HD). Peripheral arterial disease (PAD) is common in HD 
patients and is associated with increased cardiovascular morbidity and mortality rates in this 
population. To date, however, no study has specifically assessed the relationship between plas-
ma S100A12 and PAD in HD patients.  Methods:  We conducted a cross-sectional study of 152 HD 
patients in our affiliated hospital. We investigated PAD history and patient characteristics and 
quantified plasma S100A12 levels in all participants.  Results:   HD patients with PAD (n = 26; 21.9 
[13.6–33.4] ng/ml) showed significantly higher plasma S100A12 levels than HD patients without 
PAD (n = 126; 11.8 [7.5–17.6]     ng/ml; p   !   0.001). In multivariate logistic regression analysis, the 
plasma S100A12 level (odds ratio [OR] 5.71; 95% confidence interval [CI] 1.29–25.3; p = 0.022) was 
identified as an independent factor associated with PAD prevalence. Another factor associated 
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with PAD prevalence was the ankle-brachial index (OR 0.54; 95% CI 0.40–0.74; p   !   0.001).   Con-
clusion:   These results suggest that plasma S100A12 levels are strongly associated with PAD 
prevalence in ESRD patients undergoing HD.    Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  Peripheral arterial disease (PAD) is a strong predictor of subsequent all-cause and car-
diovascular mortality in end-stage renal disease (ESRD) patients  [1, 2] . Therefore, assessment 
and prevention of PAD are becoming major considerations for managing ESRD patients. Tra-
ditional risk factors for atherosclerotic cardiovascular diseases (CVDs), such as smoking, di-
abetes, hyperlipidemia, and hypertension, are associated with PAD in the general population 
  [3]  . Few studies have examined the relationship between traditional risk factors for CVD and 
PAD in ESRD   [4, 5]  . Traditional risk factors in the general population, such as diabetes and 
tobacco abuse, are also associated with PAD in dialysis patients   [5]  . In the Dialysis Outcomes 
and Practice Patterns Study   [6]  , male sex, diabetes, hypertension, and smoking together with 
dialysis duration were significantly associated with PAD. However, these CVD risk factors are 
unlikely to completely explain the high PAD prevalence in chronic kidney disease (CKD) sub-
jects because the association of CKD with PAD remains consistently strong following adjust-
ment for these and other factors   [7]  . This suggests that some components of the uremic envi-
ronment may contribute to PAD development or progression  [8] . Non-traditional risk factors, 
such as oxidative stress and advanced glycation end products (AGEs) in combination with 
receptors for AGE (RAGE), have been emphasized as factors associated with atherosclerosis 
that may play an important role in CVD development in CKD patients   [9]  .
    Enhanced RAGE expression has been observed in the peripheral blood monocytes of 
CKD patients, suggesting that RAGE may amplify ligand-induced monocyte perturbation 
and contribute to monocyte-mediated vascular inflammation in these patients   [10]  . AGEs 
were initially believed to be the main active ligands for RAGE, but subsequently, several 
other ligands for RAGE including S100A12, high mobility group box proteins, and amyloid 
fibrils have been identified   [11]  .
  Of the endogenous ligands for RAGE, emerging evidence from in vitro   and in vivo   stud-
ies supports a role for S100A12, formerly called EN-RAGE, in chronic inflammation leading 
to several pathogenic conditions such as atherosclerosis   [12, 13]  . Therefore, the binding of 
RAGE to S100A12 may further promote underlying inflammation in atherosclerosis and its 
related manifestations such as PAD.
    Based on cross-sectional analyses of PAD in 152 ESRD patients undergoing hemodialy-
sis (HD), we here assessed the relationship between plasma S100A12 levels and PAD in ESRD.
  Subjects  and  Methods 
 Patients 
  All procedures were performed in accordance with the guidelines of the Declaration of 
Helsinki on Human Experimentation. The study was approved by the Ethics Committees on 
Human Research at our institutions, and all subjects provided informed consent. Demo-
graphic and medical data including age, sex, smoking history, and comorbid conditions were 
obtained from medical records.
    The subjects were 152 ESRD patients undergoing HD who had relevant clinical infor-
mation. Patients with clinical evidence of malignant diseases or overt infection were ex-244
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cluded. All participants received conventional dialysis treatment for 3–4 h thrice a week, 
with a standard bicarbonate dialysis solution. An ankle-brachial index (ABI) measurement 
was performed on all HD patients as part of a routine clinical protocol in our affiliated hos-
pital. PAD diagnosis was based on clinical symptoms, such as intermittent claudication or 
critical limb ischemia with rest pain, ulcers, and gangrene (Fontaine stages II–IV); these 
findings were subsequently verified by computed tomography angiography and/or lower 
limb angiography. Patients with a history of percutaneous transluminal angioplasty, bypass 
grafting, and/or amputation for PAD were also included. Complaints such as numbness, 
tingling, or weakness of the lower extremities were not included as PAD symptoms because 
it was difficult to distinguish them from the symptoms of peripheral neuropathy. Symptoms 
caused by orthopedic diseases were also excluded. Coronary artery disease (CAD) was de-
fined as ischemic heart disease including myocardial infarction diagnosed on the basis of 
elevated levels of cardiac enzymes and/or typical electrocardiography changes and angina 
pectoris diagnosed by typical electrocardiography changes without elevated cardiac en-
zymes and coronary intervention (percutaneous coronary intervention or coronary artery 
bypass grafting). Stroke diagnosis was based on clinical symptoms verified by computed 
tomography and/or magnetic resonance imaging. The endpoints committee for this study 
verified the above-mentioned criteria for PAD, CAD and stroke in each participant. We in-
vestigated the medical history of all participants to diagnose PAD on the basis of the above-
mentioned criteria.
    Finally, we enrolled 26 patients with PAD (PAD alone, n = 10; PAD with CAD, n = 15; 
and PAD with CAD and stroke, n = 1) ( fig. 1 ). To determine the relationship between plasma 
S100A12 levels and PAD, patients with a clinical history of other CVDs, such as CAD and/
or stroke without PAD, were carefully excluded from the PAD group and included in the 
non-PAD group (CAD alone, n = 11; stroke alone, n = 5; and CAD with stroke, n = 3) ( fig. 1 ).
  Laboratory  Methods 
 Blood samples were obtained via vascular access when dialysis was started on a midweek 
routine dialysis day. The plasma was then immediately frozen and stored at –80    °    C until the 
time of assay. The levels of urea nitrogen, serum creatinine, total cholesterol, albumin, he-
moglobin, calcium, and phosphate as well as white blood cell and platelet counts were mea-
  Fig. 1.   Distribution of peripheral 
arterial disease (PAD) in the 
study participants. An overlap 
was observed between coronary 
artery disease (CAD), stroke, 
and PAD. The PAD group repre-
sents patients with PAD, those 
with PAD and CAD, and those 
with PAD, CAD, and stroke. 245
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sured using standard clinical laboratory methods. High-sensitivity C-reactive protein (hs-
CRP) was measured using an automatic analyzer (TBA-120FR; Toshiba, Tokyo, Japan).
    ELISA for S100A12 Quantification 
 A sandwich assay was performed using hCF128 monoclonal antibodies to quantify plas-
ma S100A12 levels   [14]  . Plasma S100A12 levels in the samples were determined by interpola-
tion of absorbance values from a calibration curve. In our previous study   [15]  , the mean   8  
SD plasma S100A12 level in 42 healthy subjects (29% male; mean age 50.5 years) was 10.8   8  
6.3 ng/ml.
  Statistical  Analysis 
  The results were expressed as mean   8   SD. Variables with a skewed distribution were 
expressed as median and interquartile range (25th–75th percentiles). Group differences were 
analyzed using Student’s t test, the Mann-Whitney U test, and     2   test for normally distrib-
uted, non-normally distributed, and discontinuous variables, respectively. Univariate logis-
tic regression analysis was performed to determine factors contributing to PAD. In this anal-
ysis, variables with a skewed distribution (plasma S100A12 and hs-CRP levels) were log 
transformed. Variables significantly associated with PAD prevalence were included in mul-
tivariate logistic regression analysis. All statistical analyses were performed using SPSS 17.0 
for Windows (IBM Japan, Tokyo, Japan). p   !   0.05 was considered statistically significant.
  R e s u l t s  
 Study  Population 
  The study subjects were 152 ESRD patients receiving maintenance HD at our affiliated 
hospital (43.4% male; mean age 65.4 years; mean HD duration 10 years). The underlying re-
nal disorders comprised diabetic nephropathy (DN) (25%) and non-diabetic renal diseases 
including chronic glomerulonephritis, hypertensive nephrosclerosis, polycystic kidney dis-
ease, and diseases of unknown etiology (75%). PAD was observed in 26 patients (17.1%;  fig. 1 ). 
The clinical characteristics of the patients are summarized in   table 1  .
    Higher Plasma S100A12 Levels in HD Patients with PAD 
 HD patients with PAD had significantly higher plasma S100A12 levels than HD patients 
without PAD (21.9 [13.6–33.4] ng/ml vs. 11.8 [7.5–17.6] ng/ml; p   !   0.001)  ( table 1 ,   fig. 2 ).  ABI, 
  Fig. 2.  Plasma S100A12 levels in hemodialysis (HD) 
patients. HD patients with PAD had significantly 
hi gh e r  p l as m a  S 1 00 A 1 2  l ev e l s  th an  HD  p a ti e n ts  
without PAD (21.9 [13.6–33.4] ng/ml vs. 11.8 [7.5–
17.6] ng/ml, p   !   0.001). 246
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DN prevalence, age, serum sodium and creatinine levels were statistically different between 
the PAD and non-PAD groups.
    Association between Plasma S100A12 Levels and PAD 
 Univariate logistic regression analysis used to determine the contributing factor for PAD 
showed that plasma S100A12 levels, ABI, DN prevalence, hs-CRP levels, and age were sig-
nificantly associated with PAD prevalence (  table 2  ). Furthermore, multivariate logistic re-
gression analysis with the above-mentioned factors showed the plasma S100A12 level (odds 
ratio [OR] 5.71; 95% confidence interval [CI] 1.29–25.3; p = 0.022) to be an independent fac-
tor associated with PAD prevalence (  table 3  ). Another independent factor associated with 
PAD prevalence was ABI (OR 0.54; 95% CI 0.40–0.74; p   !   0.001).
    To determine the relationship between the plasma S100A12 level and PAD, all subjects 
were categorized by tertiles of the plasma S100A12 level. As shown in   table 4  , after multiple 
adjustments with the significant factors in univariate logistic analysis (ABI, DN prevalence, 
hs-CRP levels, and age), a higher plasma S100A12 level was found to be correlated with an 
increased risk of PAD. Compared with patients in the first tertile, the PAD risk was signifi-
cantly higher in patients in the second (OR 6.49; 95% CI 1.10–38.4; p = 0.014) and third quar-
tiles (OR 13.7; 95% CI 2.34–80.4; p = 0.004).
Table 1.   Clinical characteristics and plasma S100A12 levels of the study groups
All
(n = 152)
PAD
(n = 26)
Non-PAD
(n = 126)
p valuea
Age, years 65.4812.2 71.289.8 63.9813.0 0.007
Male/female, n 66/86 8/18 58/68 0.153
Current smoker/non-smoker, n 14/138 3/23 11/115 0.441
Duration of HD, years 10.087.9 8.687.1 10.388.1 0.311
Systolic BP, mm Hg 143.0823.2 145.2820.8 142.5823.8 0.587
Hemoglobin, g/l 100810 100810 101811 0.731
White blood cells, !109/l 6826 826 82 0.665
Platelet, !109/l 167859 165857 168859 0.833
hs-CRP, mg/l 1.0 (0.4–3.0) 1.7 (1.0–4.3) 0.9 (0.4–2.7) 0.882
Creatinine, mol/l 9098212 8668234 9188208 0.019
Albumin, g/l 35843 5 823 5 84 0.616
Sodium, mmol/l 14083 13983 14083 0.049
Potassium, mmol/l 4.780.7 4.680.8 4.880.7 0.343
Adjusted calcium, mmol/l 2.3280.16 2.2980.02 2.3280.17 0.395
Phosphate, mmol/l 1.5480.39 1.5780.46 1.5380.37 0.635
Calcium, mmol/l ! phosphate, mmol/l 3.3880.94 3.4181.04 3.3880.92 0.881
Total cholesterol, mmol/l 4.6181.56 4.5981.36 4.6281.60 0.920
DN/non-DN, n 38/114 12/14 26/100 0.006
ABI 1.1180.18 0.9380.23 1.1580.15 <0.001
ba PWV, cm/s 1,8398516 1,9508593 1,8178499 0.239
Plasma S100A12, ng/ml 12.3 (7.8–20.0) 21.9 (13.6–33.4) 11.8 (7.5–17.6) <0.001
U  nless indicated otherwise, values are mean 8 SD or median with 25th–75th percentiles shown in parentheses.
PAD = Peripheral arterial disease; HD = hemodialysis; BP = blood pressure; hs-CRP = high-sensitivity C-reactive pro-
tein; DN = diabetic nephropathy; CVD = cardiovascular disease; ABI = ankle-brachial index; ba PWV = brachial-ankle 
pulse wave velocity.
a PAD versus non-PAD.247
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  Discussion 
  We studied 152 patients undergoing maintenance HD. HD patients with PAD had sig-
nificantly higher plasma S100A12 levels than HD patients without PAD. Plasma S100A12 
levels were identified as an independent factor associated with PAD prevalence. These find-
ings suggest a correlation between S100A12 and PAD in ESRD.
    PAD is common in dialysis patients, with a prevalence of approximately 15%   [16]  . CKD 
is associated with an increased PAD risk and recognition of this risk is growing  [17, 18] . How-
Table 2.   Univariate logistic regression analysis of clinical parameters and PAD
OR 95% CI p value
Age, years 1.06 1.02–1.10 0.009*
Male 0.52 0.21–1.29 0.157
Current smoker 1.37 0.35–5.28 0.653
Duration of HD, years 0.99 0.99–1.00 0.280
Systolic BP, mm Hg 1.01 0.99–1.02 0.584
Hemoglobin, g/l 1.01 0.97–1.05 0.729
White blood cells, !109/l 1.00 1.00–1.00 0.663
Platelet, !109/l 0.99 0.99–1.01 0.831
hs-CRP, /log mg/l 2.23 1.07–4.67 0.033*
Creatinine, mol/l 0.99 0.99–1.01 0.257
Albumin, g/l 0.98 0.87–1.10 0.711
Sodium, mmol/l 0.85 0.73–1.00 0.053
Potassium, mmol/l 0.74 0.40–1.37 0.341
Adjusted calcium, mmol/l 0.29 0.07–4.99 0.393
Phosphate, mmol/l 1.30 0.44–3.86 0.633
Calcium, mmol/l !phosphate, mmol/l 1.04 0.66–1.62 0.880
Total cholesterol, mmol/l 0.99 0.75–1.30 0.919
DN 3.30 1.36–7.98 0.008*
ABI, 0.1 unit 0.52 0.39–0.68 <0.001*
ba PWV, cm/s 1.00 1.00–1.00 0.241
Plasma S100A12, /log ng/ml 9.24 2.89–29.58 <0.001*
P  AD = Peripheral arterial disease; OR = odds ratio; 95% CI = 95% confidence interval; HD = hemodi-
alysis; BP = blood pressure; hs-CRP = high-sensitivity C-reactive protein; DN = diabetic nephropathy; 
ABI = ankle-brachial index; ba PWV = brachial-ankle pulse wave velocity. * Significant independent fac-
tors.
Table 3.   Multivariate logistic regression analysis of clinical parameters and PAD
OR 95% CI p value
Age, years 1.01 0.95–1.07 0.905
hs-CRP, /log mg/l 1.74 0.63–4.82 0.288
DN 1.98 0.65–5.97 0.228
ABI, 0.1 unit 0.54 0.40–0.74 <0.001*
Plasma S100A12, /log ng/ml 5.71 1.29–25.3 0.022*
P AD = Peripheral arterial disease; OR = odds ratio; 95% CI = 95% confidence interval; hs-CRP = high-
sensitivity C-reactive protein; DN = diabetic nephropathy; ABI =ankle-brachial index. * Significant inde-
pendent factors.248
Nephron Extra 2011;1:242–250 
 DOI:  10.1159/000335198 
EXTRA
  Shiotsu et al.: Plasma S100A12 Levels and PAD in ESRD 
www.karger.com/nne
    © 2011 S. Karger AG, Basel
  Published online: December 21, 2011     
ever, the reasons underlying the increased incidence of PAD in the CKD population remain 
unclear. Very few data are available regarding the possible association of PAD with novel 
CVD risk factors in CKD patients. The pathogenesis of atherosclerosis including PAD in the 
general population is characterized by the presence of subclinical chronic inflammation   [3]  . 
Chronic inflammation is a common feature of CKD, and approximately 30–50% of ESRD 
patients provide serological evidence   [19]  .
    S100A12 is as a potent chemoattractant; its binding to RAGE expressed by endothelial 
cells, mononuclear phagocytes, and lymphocytes triggers cellular activation and the genera-
tion of key proinflammatory mediators such as interleukin-1     and tumor necrosis factor-    
  [20]  . In the ESRD population, we found that the mean plasma S100A12 levels of 72 HD pa-
tients were 2.3-fold higher than those of control subjects. Furthermore, the maximum inti-
ma–media thickness of the carotid artery correlated with plasma S100A12 levels in HD pa-
tients   [15]  . Subsequently, a larger study conducted by our group showed that plasma S100A12 
levels were higher in 550 HD patients than in healthy subjects and that this level was an inde-
pendent factor associated with CVD prevalence  [21] . Moreover, in their ad hoc analysis of 184 
prevalent HD patients, Nakashima et al.  [22]  found that the S100A12 level was a direct predic-
tor of all-cause and CVD mortality, even after an adjustment for confounding variables. An 
animal study using transgenic overexpression of human S100A12 in murine vascular smooth 
muscle clearly demonstrated the critical role of S100A12 in directly mediating enhanced pro-
duction of reactive oxidative species and cytokine production, leading to enhanced athero-
sclerosis in ApoE null mice  [13] . These results indicate that plasma S100A12 levels may reflect 
chronic inflammation-mediated CVD. Our current analysis also supports a specific role of 
S100A12 in the development and/or progression of PAD in ESRD patients undergoing HD.
    Some limitations of this study must be acknowledged. Firstly, the study had a cross-sec-
tional design, which limited our ability to establish causal relationships. However, a recent ex-
perimental study reported an underlying relationship between S100A12 and atherosclerosis in 
CKD. Using S100A12 transgenic mice with surgically induced CKD, Gawdzik et al.  [23]  showed 
that S100A12 overexpression caused atherogenesis with increased expression of an osteoblastic 
gene in vascular smooth muscle cells. Secondly, other possible novel risk factors for PAD in 
CKD, such as Lp(a) and homocysteine levels, might be important and unfortunately were not 
measured in our study. Thirdly, although ABI is a simple, non-invasive, reliable test for the 
general population and PAD is traditionally defined by an ABI of   ^  0.9   [3]  , ABI has been sug-
gested to be unsuitable for assessing PAD in ESRD patients   [24]  . Increased arterial stiffness 
might interfere with ABI measurements and affect the sensitivity of ABI in detecting PAD 
among HD patients. Therefore, PAD diagnosis in this study was not based on ABI measure-
ments but on clinical symptoms endorsed by an imaging study. However, this might underes-
timate the existence of subclinical PAD   [25]  . Fourthly, although 10 of 26 PAD patients in this 
Table 4.   Multivariate logistic regression analysis of PAD prevalence by tertiles of plasma S100A12 levels 
in 152 HD patients
S100A12 n OR (95% CI) p value
Tertile 1 (<9.3 ng/ml) 51 1.0
Tertile 2 (9.3–16.7 ng/ml) 52 6.49 (1.10–38.4) 0.014*
Tertile 3 (>16.7 ng/ml) 49 13.7 (2.34–80.4) 0.004*
T  he values are adjusted for age, hs-CRP, ABI and the presence of diabetes mellitus. PAD = Peripheral 
arterial disease; HD = hemodialysis; OR = odds ratio; 95% CI = 95% confidence interval; hs-CRP = high-
sensitivity C-reactive protein; ABI =ankle-brachial index. * Significant independent factors versus tertile 1.249
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study had no clinical symptoms with positive imaging study of CAD and/or stroke, subclinical 
atherosclerotic lesions in addition to PAD might be co-existing, affecting the value of plasma 
S100A12 levels. Lastly, because we studied a relatively small number of patients, we cannot 
draw solid conclusions and therefore our findings need to be confirmed by a larger study. Not-
withstanding these limitations, emerging reports suggest a role for S100A12 in atherosclerosis 
  [12, 13]  , allowing us to provide a less biased estimate of the relationships observed.
  In conclusion, in a study of 152 HD patients, we showed for the first time that the plasma 
S100A12 level is an independent factor associated with PAD prevalence. We anticipate an 
important role for S100A12 as a novel biomarker for predicting PAD in ESRD patients. Pro-
spective and interventional studies are ongoing to further clarify the relationship between 
plasma S100A12 levels and PAD.
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